From shadows to spotlight: how two cases redefined Barth syndrome awareness in Belarus: two case reports with a literature review

Viktor A.  Snezhitskiy; Anna N. Biardouskaya; Naveen D. K. N. Direcksze; Narendiran Yohanathan; Kirisayon Yogarajah; Mohamed A. A. Rumi; Liudmila V. Kalatsey; Irina M. Motyuk

doi:10.18203/2320-6012.ijrms20260262

Authors

Viktor A. Snezhitskiy Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus https://orcid.org/0000-0002-1706-1243
Anna N. Biardouskaya Department of Pediatric Cardiology, Grodno State Medical University, Belarus; Regional Clinical Pediatric Hospital, Grodno, Belarus
Naveen D. K. N. Direcksze Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus https://orcid.org/0009-0005-5714-0105
Narendiran Yohanathan Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus
Kirisayon Yogarajah Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus
Mohamed A. A. Rumi Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus
Liudmila V. Kalatsey Department of Internal Medicine I, Grodno State Medical University, Belarus; Regional Cardiology Center, Grodno, Belarus
Irina M. Motyuk

DOI:

https://doi.org/10.18203/2320-6012.ijrms20260262

Keywords:

Barth syndrome, TAZ gene mutation, Cardiomyopathy cardiolipin metabolism

Abstract

Barth syndrome (BTHS) is an uncommon congenital sex-linked recessive cardiovascular disease resulting from impaired cardiolipin metabolism. The main cause of this condition is a mutation of the TAZ gene (TAFAZZIN), which activates the mitochondrial enzyme acyltransferase/transacylase, necessary for the biosynthesis of cardiolipin. The frequency of BTHS is 1 case per million men, and the total number of reported cases worldwide is about 250. The article presents 2 cases of BTHS diagnosis in the same city. A 9-year-old boy who was admitted to the intensive care unit of the Grodno Regional Children's Clinical Hospital was identified in pediatric observation. In the case of an adult patient, an 18-year-old boy was hospitalized in the Grodno Regional Cardiology Center with an exacerbation of heart failure. In both cases, cardiovascular complications were identified when an adult had an atypical phenotype of cardiomyopathy-dilated right ventricular cardiomyopathy and a broad spectrum of comorbidities, and a pediatric patient had visible cardiomegaly, which may be associated with changes in energy metabolism in the heart over time, as evidenced by imaging results. In addition, both patients underwent thorough genetic testing, which confirmed the diagnosis of BTHS in these two cases. This article illustrates the importance of raising awareness about BTHS in the Eastern European region.

Metrics

Metrics Loading ...

References

Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IEM, Veer-Korthof ETVT, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurological Sci. 1983;62(1-3):327-55. DOI: https://doi.org/10.1016/0022-510X(83)90209-5

Jefferies JL. Barth syndrome. Am J Med Genetics Part C: Seminars in Medical Genetics. 2013;163(3):198-205. DOI: https://doi.org/10.1002/ajmg.c.31372

Miller PC, Ren M, Schlame M, Toth MJ, Phoon CK. A Bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population. J Pediatr. 2020;217:139-44. DOI: https://doi.org/10.1016/j.jpeds.2019.09.074

Dudek J. Role of cardiolipin in mitochondrial signaling pathways. Front Cell Developm Biol. 2017;5:90. DOI: https://doi.org/10.3389/fcell.2017.00090

Pfeiffer K, Gohil V, Stuart RA, Hunte C, Brandt U, Greenberg ML, et al. Cardiolipin stabilizes respiratory chain supercomplexes. J Biological Chem. 2003;278(52):52873-80. DOI: https://doi.org/10.1074/jbc.M308366200

Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292(1):C33-44. DOI: https://doi.org/10.1152/ajpcell.00243.2006

Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Role of cardiolipin in mitochondrial function and dynamics in health and disease: molecular and pharmacological aspects. Cells. 2019;8(7):728. DOI: https://doi.org/10.3390/cells8070728

Oemer G, Koch J, Wohlfarter Y, Alam MT, Lackner K, Sailer S, et al. Phospholipid acyl chain diversity controls the tissue-specific assembly of mitochondrial cardiolipins. Cell Rep. 2020;30(12):4281-91. DOI: https://doi.org/10.1016/j.celrep.2020.02.115

Ørstavik KH, Ørstavik RE, Naumova AK, D'Adamo P, Gedeon A, Bolhuis PA, et al. X chromosome inactivation in carriers of Barth syndrome. Am J Human Genetics. 1998;63(5):1457-63. DOI: https://doi.org/10.1086/302095

Cosson L, Toutain A, Simard G, Kulik W, Matyas G, Guichet A, et al. Barth syndrome in a female patient. Molecular Genet Metabol. 2012;106(1):115-20. DOI: https://doi.org/10.1016/j.ymgme.2012.01.015

Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet J Rare Dis. 2013;8(1):23. DOI: https://doi.org/10.1186/1750-1172-8-23

Houtkooper RH, Rodenburg RJ, Thiels C, van Lenthe H, Stet F, Poll-The BT, et al. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. Analytical Biochem. 2009;387(2):230-7.

Ferreira C, Pierre G, Thompson R, Vernon H. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. Anal Biochem. 2009;387(2):230-7. DOI: https://doi.org/10.1016/j.ab.2009.01.032

Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, et al. The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genetics Part A. 2012;158(11):2726-32. DOI: https://doi.org/10.1002/ajmg.a.35609

Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics. 2006;118(2):e337-46. DOI: https://doi.org/10.1542/peds.2005-2667

Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics Med. 2024;26(7):101138. DOI: https://doi.org/10.1016/j.gim.2024.101138

Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Heart Failure Rev. 2021;26(2):237-53. DOI: https://doi.org/10.1007/s10741-020-10031-3